Alan Bao
Biography
Overview
Alan Bao is a partner in the firm's Mergers & Acquisitions practice group, based in Beijing.
Alan focuses his practice on mergers and acquisitions, capital markets, and other general corporate matters. He represents clients in their going private, Hong Kong initial public offerings (IPOs), as well as in FIE, employment, and IP enforcement matters.
Alan understands that legal challenges can interrupt companies' foci from their core business activities. He skillfully crafts solutions that enable his clients to retain energy for business management and development. Alan's clients range from start-ups to Fortune 500 corporations and operate in a wide variety of industries such as financial services (including investment banks and private equity), consumer electronics and technology, health care, biotechnology, pharmaceuticals, gaming, entertainment, and aviation.
Prior to joining White & Case, Alan worked at the Beijing and Los Angeles offices of another international firm.
Experience
Alan's recent representative experience includes advising:
Representation of a buyer consortium in the proposed going private transaction of 111, Inc. (NASDAQ:YI).
Representation of Acotec Scientific on its approximately US$520 million voluntary partial offer by Boston Scientific.
Representation of buyer consortium led by Fang Holdings (OTC: SFUNY) in a going private transaction involving China Index Holdings (NASDAQ: CIH) valued at approximately US$92 million.
Representation of a buyer consortium led by Yunfeng Capital, TF Capital, GIC and management in connection with the acquisition of Cellular Biomedicine Group (NASDAQ: CBMG), a biopharmaceutical company developing proprietary cell therapies for the treatment of cancer and degenerative diseases, in a "going private" transaction valued at approximately US$410 million.
Representation of SEEK Limited in the sale of a controlling interests in a leading Chinese recruitment website at a US$1.7 billion valuation to Primavera-led consortium.
Representation of TTM Technologies, Inc. (NASDAQ: TTMI) in the sale of substantially all of its China-based mobility business to Chinese consortium AKM Meadville Electronics (Xiamen) Co., Ltd. for a combination of $550 million in cash and an estimated $110 million in retained accounts receivable.
Representation of the buyer group in a proposed going private transaction of China XD Plastics (NASDAQ: CXDC).
Representation of a buyer consortium led by the management in a "going private" transaction of SORL Auto Parts, Inc. (NASDAQ: SORL) valued at approximately US$96 million.
Representation of the PKU-VMing (SZSE:002581) buyer consortium in a competing going private bid against management for a Chinese biopharmaceutical and vaccine company Sinovac Biotech Ltd. (NASDAQ: SVA).
Representation of Chinese hotel chain Homeinns (NASDAQ: HMIN) in US$1.75 billion going private transaction.
